LRMR: Larimar Therapeutics, Inc. insider trading, 5% holders and institutional ownership
From public SEC filings: open-market insider purchases and sales (Form 4, last 180 days), holders of 5% or more (Schedules 13D and 13G) and institutional ownership (Form 13F). Insider and 5% data delayed 48 hours.
Insider trading
0 open-market buys totaling - and 0 sales totaling - in the last 180 days.
Institutional ownership (Q2 2026)
163 institutions reported holding $290.92M of Larimar Therapeutics, Inc. on Form 13F (162 the quarter before). 31 opened a new position and 29 sold out. Shares held by institutions: +9%.
| Largest holders | Shares | Value |
|---|---|---|
| DEERFIELD MANAGEMENT COMPANY, L.P. | 35,606,974 | $108.60M |
| Blue Owl Capital Holdings LP | 9,163,157 | $27.95M |
| BlackRock, Inc. | 5,678,035 | $17.32M |
| Defilade Capital Management, L.P. | 3,670,135 | $11.19M |
| Driehaus Capital Management LLC | 3,163,423 | $9.65M |
| VANGUARD CAPITAL MANAGEMENT LLC | 2,974,901 | $9.07M |
| RTW INVESTMENTS, LP | 2,565,999 | $7.83M |
| AQR CAPITAL MANAGEMENT LLC | 2,371,414 | $7.23M |
| MARSHALL WACE, LLP | 2,012,458 | $6.14M |
| DAFNA Capital Management LLC | 2,008,164 | $6.12M |
Clinical trial readouts
1 Phase 2 or 3 trials by Larimar Therapeutics, Inc. with a primary completion date in the last 90 days or the next 12 months and no results posted yet, from ClinicalTrials.gov. (est.) = company estimate.
| Primary completion | Drug | Condition | Phase | Patients | Status | Trial |
|---|---|---|---|---|---|---|
| 2027-01 (est.) | CTI-1601 | Friedreich Ataxia | Phase 2 | 85 | Recruiting | NCT06447025 |
Get new insider and activist filings the morning after: daily alerts. Not investment advice.